Loading clinical trials...
Loading clinical trials...
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG
Conditions
Interventions
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))
PANVAC
Locations
2
United States
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Start Date
December 18, 2013
Primary Completion Date
September 18, 2018
Completion Date
May 2, 2019
Last Updated
July 1, 2025
NCT06257264
NCT07206225
NCT03317158
NCT06770582
NCT06253871
NCT06510374
Lead Sponsor
National Cancer Institute (NCI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions